Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

Elekta wins public tender to deliver several Harmony linear accelerators to help meet demand for cancer treatments

News | Linear Accelerators

Elekta Continues to Support Ukrainian Cancer Patients with Latest Radiation Therapy Equipment

October 25, 2023 — A new order for several Elekta Harmony linear accelerators (linacs) in Ukraine will complement the ...

October 25, 2023

The Centers for Medicare and Medicaid Services (CMS) recently released its final National Coverage Determination Reconsideration for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease

News | PET Imaging

CMS Responds to Public Comments Received on Beta Amyloid PET Scan Proposed Coverage

October 24, 2023 — The Centers for Medicare and Medicaid Services (CMS) recently released its final National Coverage ...

October 24, 2023

Comprehensive restoration of legacy machine offers the opportunity for sustainable solution

News | Proton Therapy

IBA Plans Total System Restoration on its First-ever Proton Therapy Installation

October 23, 2023 — IBA, a world leader in particle accelerator technology and the world’s leading provider of proton ...

October 23, 2023

Sponsored Content

Staging F-18 FDG PET/CT images of adenocarcinoma in the RUL of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. Images courtesy of Dr. Jay Kikut and UVM

Blog | PET-CT

Digital PET Balances Scan Time and Resolution

Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both. The key is the ...

October 25, 2018

Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4

News | Radiopharmaceuticals and Tracers

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

October 20, 2023

Human life-like in vitro model of radiation damage sustained to the lung opens an unprecedented window into the early disease process, and opportunities for drug development

News | Radiation Therapy

Human Lung Chip Leveraged to Faithfully Model Radiation-induced Lung Injury

October 19, 2023 — The lung is one of the tissues most sensitive to radiation in the human body. People exposed to high ...

October 19, 2023

Medicare leaves coverage determination for amyloid PET in dementia care to MACs

News | PET Imaging

CMS Expands Access to Beta Amyloid PET for Medicare Beneficiaries

October 18, 2023 — The Centers for Medicare and Medicaid Services (CMS) announced it will no longer require coverage ...

October 18, 2023

New company will advance Actinium-225 technologies

News | Radiopharmaceuticals and Tracers

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

October 18, 2023 —ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian ...

October 18, 2023

Radionetics initiates its first clinical program targeting MC2R

News | Radiation Oncology

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

October 17, 2023 — Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and ...

October 17, 2023

A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical diagnostics - [68Ga]FAPI-46 and outside-U.S. rights for [18F]FAPI-74

News | Radiopharmaceuticals and Tracers

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE) ...

October 11, 2023

68Ga-ABY-025 PET/CT and 18F-FDG PET/CT images at baseline with 18F-FDG PET/CT follow-up after 2 cycles of treatment in biopsy-confirmed HER2-positive disease

News | Breast Imaging

Whole-body PET/CT Predicts Response to HER2-targeted Therapy in Metastatic Breast Cancer Patients

October 11, 2023 — A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth ...

October 11, 2023

Dr. Michael Butkus is Co-medical Director and Head of Proton Physics at the Dwoskin Proton Center at the Sylvester Comprehensive Cancer Center

Feature | Proton Therapy | By Christine Book

One on One … with Michael Butkus, PhD

A University of Miami Radiation Oncology department summary noted: “In radiation oncology, the art of patient care meets ...

October 11, 2023

Videos | Proton Therapy

VIDEO: Advancements in Proton Therapy

Tune in to ITN’s latest “One on One” video series with Michael Butkus, PhD, for insights into proton therapy ...

October 10, 2023

Technology-powered collaboration aims to deliver AI-enabled devices and digital solutions at the enterprise level to increase clinical and operational efficiencies, drive workflow enhancements and improve patient outcomes

News | Radiology Business

GE HealthCare and University Hospitals Enter 10-Year Strategic Collaboration to Contemporize Its Imaging Fleet and Implement Enterprise Digital Solutions to Help Improve Patient Care and Optimize Processes

October 10, 2023 — Realizing a vision to deliver the best care to patients close to where they live in northern Ohio, GE ...

October 10, 2023

POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer.

News | Radiopharmaceuticals and Tracers

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

October 5, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

October 05, 2023

News | Radiation Therapy

RefleXion Showcases Breakthrough SCINTIX Biology-Guided Radiotherapy and Highlights New Research at ASTRO 2023 Meeting

September 28, 2023 — RefleXion Medical, a therapeutic oncology company, announced the company will showcase the ...

September 28, 2023

POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis

News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

September 27, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

September 27, 2023

A modern collection of imaging innovations offers a new path to healthcare and medical research, framing a new era of medical diagnostic solutions

Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

The Full Body Imaging Movement: A Strategic Upgrade of the MRI

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

September 25, 2023

Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT mаchines, using the perovskite-based photoconverters

News | X-Ray

Moscow Scientists Initiate Groundbreaking Testing of X-ray Machine Detectors

September 21, 2023 — Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT ...

September 21, 2023

Advancements in research, technology and partnerships are combining to enhance availability and access

Feature | Proton Therapy | By Christine Book

Targeting Cancer, Tracking Collaboration: A Progress Report on Proton Therapy

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

September 21, 2023

This molecule may significantly expand the patient population eligible for SCINTIX therapy to patients with solid tumor cancers of any stage in a manner that may improve both outcomes and procedural workflow

News | Radiation Therapy

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

September 20, 2023